RT Journal Article
SR Electronic
T1 Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.20.21268048
DO 10.1101/2021.12.20.21268048
A1 Syed, Abdullah M.
A1 Ciling, Alison
A1 Khalid, Mir M.
A1 Sreekumar, Bharath
A1 Chen, Pei-Yi
A1 Kumar, G. Renuka
A1 Silva, Ines
A1 Milbes, Bilal
A1 Kojima, Noah
A1 Hess, Victoria
A1 Shacreaw, Maria
A1 Lopez, Lauren
A1 Brobeck, Matthew
A1 Turner, Fred
A1 Spraggon, Lee
A1 Taha, Taha Y.
A1 Tabata, Takako
A1 Chen, Irene P.
A1 Ott, Melanie
A1 Doudna, Jennifer A.
YR 2022
UL http://medrxiv.org/content/early/2022/01/02/2021.12.20.21268048.abstract
AB The Omicron SARS-CoV-2 virus contains extensive sequence changes relative to the earlier arising B.1, B.1.1 and Delta SARS-CoV-2 variants that have unknown effects on viral infectivity and response to existing vaccines. Using SARS-CoV-2 virus-like particles (SC2-VLPs), we examined mutations in all four structural proteins and found that Omicron showed 3-fold higher capsid assembly and cell entry relative to Delta, a property conferred by S and N protein mutations. Thirty-eight antisera samples from individuals vaccinated with Pfizer/BioNTech, Moderna, Johnson & Johnson vaccines and convalescent sera from unvaccinated COVID-19 survivors had 15-fold lower efficacy to prevent cell transduction by VLPs containing the Omicron mutations relative to the ancestral B.1 spike protein. A third dose of Pfizer vaccine elicited substantially higher neutralization titers against Omicron, resulting in detectable neutralizing antibodies in 8 out of 8 subjects compared to 1 out of 8 pre-boost. Furthermore, the monoclonal antibody therapeutics Casirivimab and Imdevimab had robust neutralization activity against B.1, B.1.1 or Delta VLPs but no detectable neutralization of Omicron VLPs. Our results suggest that Omicron is more efficient at assembly and cell entry compared to Delta, and the antibody response triggered by existing vaccines or previous infection, at least prior to boost, will have limited ability to neutralize Omicron. In addition, some currently available monoclonal antibodies will not be useful in treating Omicron-infected patients.One-Sentence Summary Omicron SARS-CoV-2 virus-like particles have enhanced infectivity that is only weakly neutralized by vaccination without boost or prior infection, or antibody therapeutics.Competing Interest StatementAMS and JAD are inventors on a patent application filed by the Gladstone Institutes and the University of California that covers the method and composition of SARS-CoV-2 VLP preparations for RNA transduction and expression in cells.Funding StatementThis project was funded by a grant to JAD from the National Institutes of Health (R21AI59666) and by support from the Howard Hughes Medical Institute and the Gladstone Institutes. AMS acknowledges support from the National Sciences and Engineering research Council of Canada (NSERC PDF-533021-2019), IPC received support from the NIH (F31AI164671-01), and MO received support from the Roddenberry Foundation and a gift from Pam and Ed Taft.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Advarra gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.